Benicar HCT is a combination pill of an ARB (angiotensin receptor blocker), Olmesartan, and a thiazide diuretic. It is used in the treatment of hypertension.
Olmesartan and hydrochlorothiazide (Benicar HCT) Uses:
-
Hypertension:
- Hypertension management (not indicated for initial treatment)
Olmesartan and hydrochlorothiazide (Benicar HCT) Dose in Adults
Olmesartan and hydrochlorothiazide (Benicar HCT) Dose in the treatment of Hypertension:
P/O:
-
Replacement therapy:
- For individual titrated agents, combination product may be substituted.
-
Initiation of combination therapy when monotherapy has failed to achieve desired effects:
-
Patients currently on olmesartan monotherapy:
- Initial:
- Daily Olmesartan 40 mg per hydrochlorothiazide 12.5 mg once.
- After 2 to 4 weeks, may titrate dose (max: olmesartan 40 mg per hydrochlorothiazide 25 mg per day).
-
Patients currently on hydrochlorothiazide monotherapy:
- Initial:
- Olmesartan 20 mg once daily with hydrochlorothiazide 12.5 mg.
- After two to four weeks, the dosage may be increased (max: olmesartan 40 mg/hydrochlorothiazide 25 mg daily).
-
Use in children:
Not recommended.
Pregnancy Risk Factor D
- [US Boxed Warning]
- Drugs that interfere with the renin-angiotensin system can damage or even kill a developing foetus.
- Stop having a baby if you are pregnant.
- You can also contact individual agents.
Use of hydrochlorothiazide and olmesartan during lactation
- It is unknown if breast milk contains olmesartan.
- Thiazide diuretics in breast milk are excreted.
- The manufacturer advises making a decision regarding whether to cease nursing or stop using the medication.
- This consideration should be taken in light of the possibility of serious adverse reactions in the infant while nursing.
- Talk to individual agents.
Olmesartan and hydrochlorothiazide (Benicar HCT) Dose in Kidney Disease:
-
CrCl >30 mL/minute:
- No dosage change is required.
-
CrCl ≤30 mL/minute:
- No dosage modifications are mentioned in the manufacturer's labelling (has not been studied).
Olmesartan and hydrochlorothiazide (Benicar HCT) Dose in Liver Disease:
- There are no dose modifications mentioned in the combined product's manufacturer labelling.
- In patients with significant hepatic impairment, a daily maximum of olmesartan 20 mg/hydrochlorothiazide 12.5 mg has been advised (Olmetec Plus Canadian product labeling).
Side Effects of Olmesartan and hydrochlorothiazide (Benicar HCT):
-
Central Nervous System:
- Dizziness
-
Endocrine & Metabolic:
- Hyperuricemia
-
Gastrointestinal:
- Nausea
-
Respiratory:
- Upper Respiratory Tract Infection
Side effects of Olmesartan and hydrochlorothiazide (Benicar HCT) (frequency not known):
-
Cardiovascular:
- Chest Pain
- Peripheral Edema
-
Central Nervous System:
- Vertigo
-
Dermatologic:
- Skin Rash
-
Endocrine & Metabolic:
- Hyperglycemia
- Hyperlipidemia
-
Gastrointestinal:
- Abdominal Pain
- Diarrhea
- Dyspepsia
- Gastroenteritis
-
Genitourinary:
- Hematuria
-
Hepatic:
- Increased Serum Transaminases
-
Neuromuscular & Skeletal:
- Back Pain
- Arthralgia
- Arthritis
- Increased Creatine Phosphokinase
- Myalgia
-
Respiratory:
- Cough
Contraindications to Olmesartan and hydrochlorothiazide (Benicar HCT):
- Hypersensitivity
- Patients with diabetes mellitus are not advised to utilise aliskiren concurrently.
- Anuria
Notice:
- The scientific validity of the claim that this medication is contraindicated when used with other sulfonamide-containing drug classes has been questioned.
- For more information, go to "Warnings/Precautions."
- There is only weak evidence that angiotensin II receptor blockers and diuretics related to thiazides can cause allergic reactions.
- Due to similarities in chemical structure and pharmacologic actions, cross-sensitivity may be conceivable.
Canadian labeling:
-
Additional contraindications not listed in the US labeling:
- Hypersensitivity to other medications produced from sulfonamides
- Patients with severe or moderate renal impairment are advised to utilise aliskiren concurrently. GFR of 60 mL/min/1.73 m2
Warnings and precautions
-
Angioedema
- Angioedema may be caused by some angiotensin II antagonists. It has been reported that it is rare (ARBs), and can occur anytime during treatment, especially after the first dose.
- It might affect the colon, head and neck, which could compromise the airway (presenting as abdominal pain).
- Patients who have genetic, idiopathic, or other types of angioedema may be more susceptible.
- Especially if the larynx, glottis, or tongue are implicated. They may be linked to airway blockage. As a result, frequent monitoring may be required.
- Patients who have had previous airway surgery may be at greater risk for obstruction.
- Stop all therapy immediately if angioedema develops
- It is crucial to be aggressive in early management.
- It may be necessary to administer epinephrine intramuscularly (IM).
- Patients who have angioedema caused by ARBs should not be readministered.
-
Electrolyte disturbances:
- Angiotensin II receptor antagonists may cause hyperkalemia.
- Renal impairment, diabetes mellitus, and concurrent use of potassium-sparing diuretics or potassium supplements are risk factors.
- These agents should be used with caution.
- Hypokalemia, hypochloremic acidosis, hypomagnesemia and hyponatremia can be caused by Thiazide diuretics.
-
Gastrointestinal effects:
- With olmesartan, symptoms of sprue-like intestinal disease (i.e. severe, chronic diarrhea with significant weight gain) may be present years after the initial treatment with villous atrophy, which is commonly seen on intestinal biopsy.
- After other causes have been checked out, stop the medication and research other antihypertensive therapies.
- In a series of 22 patients, clinical and histologic improvements were observed after treatment was stopped (Rubio-Tapia 2012).
-
Gout
- Gout can be caused by a family history or chronic renal disease.
- Doses greater than 25 mg daily may increase the risk.
-
Hypersensitivity reactions
- Hypersensitivity reactions can occur with hydrochlorothiazide.
- Patients who have a history of bronchial asthma or allergies are more vulnerable.
-
Hypotension
- Patients who have been treated with high-dose diuretics may experience symptoms of hypotension upon initiation.
- Correct volume depletion must be done before administration.
- To further treatment with olmesartan/hydrochlorothiazide, his transient hypotensive response is not a contraindication.
-
Ocular effects
- Hydrochlorothiazide may produce acute transitory myopia or acute angle-closure vision. This typically happens hours to weeks after initiating.
- For patients who are having significant ocular or visual pain, stop all therapy right away.
- If intraocular pressure continues to increase, more treatments might be necessary.
- A history of penicillin allergy or sulfonamide allergy could be a risk factor.
-
Photosensitivity
- Hydrochlorothiazide may be a possible cause.
-
Renal function deterioration:
- In patients whose GFR depends on efferent arterial vasoconstriction and who have poor renal flow (due to kidney artery stenosis, for example, or heart failure), this may be linked to impaired renal function and increases in serum creatinine (angiotensin II).
- Oliguria, severe renal failure, and progressive azotemia could result from a worsening.
- Small increases in serum creatinine may happen after starting.
- Patients with significant and progressive impairment of renal function should be considered for discontinuation.
-
Allergy to sulfonamide ("sulfa")
- Patients with an allergy to sulfonamides may have a wide contraindication when using medications that contain a sulfonamide chemical class.
- It is feasible for members of the same class to interact with one another (eg, between two antibiotic sulfonamides).
- Concerns about cross-reactivity have been expressed for all substances with the sulfonamide structure.
- It is rare, if not impossible, for antibiotic and non-antibiotic sulfonamides to interact with one another. A deeper comprehension of allergy processes has proven this.
- Nonantibiotic sulfonamides are not likely to cause anaphylaxis (a mechanism of cross-reaction due antibody production).
- Less is known about type IV T-cell reactions, such as maculopapular skin rash. Based on what is known at the moment, it is difficult to rule out this possibility.
- These classes are sometimes avoided by some clinicians in severe cases of reactions (Stevens Johnson syndrome/TEN).
-
Aortic/mitral stenosis:
- Patients with severe aortic/mitral stenosis should use omesartan with caution.
-
Bariatric surgery
- Dehydration
- Avoid diuretics immediately after bariatric surgery.
- Possible electrolyte disturbances or dehydration.
- Once oral fluid intake goals have been met, diuretics can be resumed if indicated.
-
Diabetes:
- Patients with diabetes mellitus or prediabetes should use hydrochlorothiazide with caution.
- Possibly will have a shift in glucose regulation
-
Hepatic impairment
- Patients with significant hepatic impairment should be handled with caution.
- Avoid electrolyte imbalances and acid/base imbalances in severe or progressive hepatic diseases to avoid hepatic complications.
-
Hypercalcemia:
- Renal calcium excretion may be reduced by thiazide diuretics.
- Patients with hypercalcemia should be advised to stop using it.
-
Hypercholesterolemia:
- In patients with high or moderate cholesterol levels, exercise caution.
- Thiazides have been linked to higher levels of triglycerides and cholesterol.
-
Parathyroid disease
- Calcium excretion is decreased by thiazide diuretics.
- Long-term use can lead to pathologic changes in parathyroid glands, including hypophosphatemia and hypercalcemia.
- It is important to stop using it before testing for parathyroid function.
-
Renal artery stenosis
- In individuals with unstented unilateral or bilateral renal artery stenosis, use olmesartan with caution.
- It is advised to stay away from utilising this device if there is unstented bilateral renal arterial stenosis.
-
Renal impairment
- When treating patients with renal impairment, exercise caution.
- Patients with impaired renal function may experience azotemia as a result of the cumulative effects hydrochlorothiazide has on their bodies.
- Hydrochlorothiazide is not effective in severe renal disease.
- Patients with anuria are not advised to use this product.
-
Systemic lupus erythematosus (SLE):
- SLE activation or exacerbation can be caused by hydrochlorothiazide.
Olmesartan and hydrochlorothiazide: Drug Interaction
|
Risk Factor C (Monitor therapy) |
|
|
Ajmaline |
Sulfonamides might make ajmaline more harmful or poisonous. In particular, there may be an elevated risk for cholestasis. |
|
Alcohol (Ethyl) |
Increases the effectiveness of thiazide and thiazide-like diuretics in lowering orthostatic blood pressure. |
|
Alfuzosin |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Allopurinol |
The possibility of allergic or hypersensitive reactions to allopurinol may be increased by thiazide and thiazide-like diuretics. The serum concentration of Allopurinol may rise in response to thiazides and thiazide-like diuretics. In particular, Thiazide Diuretics may raise Oxypurinol's levels, an active metabolite of Allopurinol. |
|
Aminolevulinic Acid (Topical) |
Aminolevulinic Acid's photosensitizing impact may be enhanced by photosensitizing agents (Topical). |
|
Amphetamines |
May lessen the effectiveness of antihypertensive agents. |
|
Angiotensin II |
The therapeutic benefit of angiotensin II may be reduced by receptor blockers. |
|
Anticholinergic Agents |
May raise the levels of thiazide and thiazide-like diuretics in the blood. |
|
Antidiabetic Agents |
The therapeutic value of anti-diabetic agents may be diminished by thiazide and thiazide-like diuretics. |
|
Antidiabetic Agents |
The therapeutic benefit of anti-diabetic agents may be reduced by hyperglycemia-associated agents. |
|
Antipsychotic Agents (Second Generation [Atypical]) |
Antipsychotic drugs' hypotensive effects may be enhanced by blood pressure-lowering medications (Second Generation [Atypical]). |
|
Barbiturates |
Increases the effectiveness of thiazide and thiazide-like diuretics in lowering orthostatic blood pressure. |
|
Barbiturates |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Benperidol |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Beta2-Agonists |
Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact. |
|
Brigatinib |
May lessen the effectiveness of antihypertensive agents. Antihypertensive Agents' bradycardic action may be strengthened by brutinib. |
|
Brimonidine (Topical) |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Calcium Salts |
The excretion of calcium salts may be decreased by thiazide and thiazide-like diuretics. Metabolic alkalosis can also be brought on by continued concurrent usage. |
|
CarBAMazepine |
Thiazide and Thiazide-Like Diuretics may intensify CarBAMazepine's negative/toxic effects. Particularly, there could be a higher risk of hyponatremia. |
|
Cardiac Glycosides |
Cardiac Glycosides may have an increased negative or toxic effect when used with thiazide and thiazide-Like Diuretics. Particularly, the hypokalemic and hypomagnesemic impact of thiazide diuretics may worsen cardiac glycoside toxicity. |
|
Corticosteroids (Orally Inhaled) |
Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact. |
|
Corticosteroids (Systemic) |
Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact. |
|
Cyclophosphamide |
Thiazide and Thiazide-Like Diuretics may intensify Cyclophosphamide's harmful or hazardous effects. Particularly, granulocytopenia could be worsened. |
|
CycloSPORINE (Systemic) |
CycloSPORINE's hyperkalemic impact may be enhanced by angiotensin II receptor blockers (Systemic). |
|
Dapoxetine |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Dexketoprofen |
Sulfonamides' harmful or poisonous effects could be amplified. |
|
Dexmethylphenidate |
May lessen the effectiveness of antihypertensive agents. |
|
Diacerein |
Could make diuretics' therapeutic effects stronger. Particularly, there may be a higher chance of hypokalemia or dehydration. |
|
Diazoxide |
Thiazide and Thiazide-Like Diuretics may intensify Diazoxide's harmful or toxic effects. |
|
Diazoxide |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Drospirenone |
Drospirenone's hyperkalemic impact may be enhanced by angiotensin II receptor blockers. |
|
DULoxetine |
The hypotensive impact of DULoxetine may be enhanced by blood pressure lowering medications. |
|
Eltrombopag |
May raise the level of OATP1B1/1B3 (SLCO1B1/1B3) Substrates in the serum. |
|
Eplerenone |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Gemfibrozil |
May raise the level of OATP1B1/1B3 (SLCO1B1/1B3) Substrates in the serum. Agents indicated as exceptions should be examined in separate drug interaction monographs. |
|
Heparin |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Heparins (Low Molecular Weight) |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Herbs (Hypertensive Properties) |
May lessen the effectiveness of antihypertensive agents. |
|
Herbs (Hypotensive Properties) |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Hypotension-Associated Agents |
The hypotensive action of hypotension-associated agents may be strengthened by blood pressure lowering medications. |
|
Ipragliflozin |
The toxic and harmful effects of thiazide and thiazide-like diuretics may be increased. In particular, there may be an elevated risk for intravascular volume depletion. |
|
Ivabradine |
The arrhythmogenic impact of ivabradine may be enhanced by thiazide and thiazide-like diuretics. |
|
Levodopa-Containing Products |
Levodopa-Containing Products' hypotensive effects may be strengthened by blood pressure-lowering medications. |
|
Licorice |
Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact. |
|
Lormetazepam |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Methylphenidate |
May lessen the effectiveness of antihypertensive agents. |
|
Molsidomine |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Multivitamins/Fluoride (with ADE) |
Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact. |
|
Multivitamins/Minerals (with ADEK, Folate, Iron) |
The effect of multivitamins and minerals on hypercalcemia may be enhanced by thiazide and thiazide-like diuretics (with ADEK, Folate, Iron). |
|
Multivitamins/Minerals (with AE, No Iron) |
The serum concentration of multiple vitamins and minerals may rise after taking thiazide and thiazide-like diuretics (with AE, No Iron). Particularly, thiazide diuretics may reduce calcium excretion, and long-term concurrent usage may result in metabolic alkalosis. |
|
Naftopidil |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Neuromuscular-Blocking Agents (Nondepolarizing) |
The neuromuscular-blocking action of neuromuscular-blocking agents may be enhanced by thiazide and thiazide-like diuretics (Nondepolarizing). |
|
Nicergoline |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Nicorandil |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Nicorandil |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Nitroprusside |
Nitroprusside's hypotensive impact may be strengthened by blood pressure-lowering medications. |
|
Nonsteroidal Anti-Inflammatory Agents |
Nonsteroidal Anti-Inflammatory Agents' nephrotoxic effects may be intensified by thiazide and thiazide-like diuretics. Thiazide and Thiazide-Like Diuretics may have less of a therapeutic impact when used with nonsteroidal anti-inflammatory drugs. |
|
Nonsteroidal Anti-Inflammatory Agents |
Nonsteroidal Anti-Inflammatory Agents' negative/toxic effects may be amplified by angiotensin II receptor blockers. In particular, the combination may cause a marked decline in renal function. Angiotensin II Receptor Blockers' therapeutic impact may be lessened by non-steroidal anti-inflammatory drugs. Both glomerular filtration rate and renal function may be considerably reduced by the combination of these two drugs. |
|
Opioid Agonists |
Could make diuretics' harmful or toxic effects worse. Opioid antagonists may reduce diuretics' therapeutic benefit. |
|
Oxcarbazepine |
Thiazide and Thiazide-Like Diuretics may intensify OXcarbazepine's negative/toxic effects. Particularly, there could be a higher risk of hyponatremia. |
|
Pentoxifylline |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Pholcodine |
Pholcodine's hypotensive impact may be strengthened by blood pressure lowering medications. |
|
Phosphodiesterase 5 Inhibitors |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Porfimer |
The photosensitizing effect of Porfimer may be strengthened by photosensitizing agents. |
|
Potassium Salts |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Potassium-Sparing Diuretics |
Potassium-Sparing Diuretics may have a stronger hyperkalemic impact when used with Angiotensin II Receptor Blockers. |
|
Prostacyclin Analogues |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Quinagolide |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Ranolazine |
Angiotensin II Receptor Blockers' hazardous or harmful effects might be exacerbated. |
|
Reboxetine |
Thiazide and Thiazide-Like Diuretics might have an enhanced hypokalemic impact. |
|
Selective Serotonin Reuptake Inhibitors |
The hyponatremic effects of thiazide and thiazide-like diuretics may be enhanced. |
|
Tacrolimus (Systemic) |
Tacrolimus's hyperkalemic impact may be enhanced by angiotensin II receptor blockers (Systemic). |
|
Teriflunomide |
May raise the level of OATP1B1/1B3 (SLCO1B1/1B3) Substrates in the serum. |
|
Toremifene |
Toremifene's hypercalcemic impact may be enhanced by thiazide and thiazide-like diuretics. |
|
Trimethoprim |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. |
|
Valsartan |
HydroCHLOROthiazide may increase Valsartan's ability to lower blood pressure. The serum concentration of HydroCHLOROthiazide may rise in response to Valsartan. |
|
Verteporfin |
Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. |
|
Vitamin D Analogs |
The hypercalcemic impact of vitamin D analogues may be enhanced by thiazides and thiazide-like diuretics. |
|
Yohimbine |
May lessen the effectiveness of antihypertensive agents. |
|
Risk Factor D (Consider therapy modification) |
|
|
Aliskiren |
Angiotensin II Receptor Blockers' hyperkalemic impact might be strengthened. The hypotensive effects of angiotensin II receptor blockers may be strengthened by aliskiren. Angiotensin II Receptor Blockers' nephrotoxic effects may be made worse by aliskiren. Treatment: It is not advised for diabetic patients to take aliskiren along with ACEIs or ARBs. Combination therapy should be avoided in other patients, especially when CrCl is less than 60 mL/min. If combined, keep a close eye on your blood pressure, potassium, and creatinine levels. |
|
Amifostine |
Amifostine's hypotensive impact may be strengthened by blood pressure lowering medications. Treatment: Blood pressure-lowering drugs need to be avoided for 24 hours before amifostine is administered when used at chemotherapeutic doses. Amifostine should be used if blood pressure medication cannot be discontinued. |
|
Angiotensin-Converting Enzyme Inhibitors |
Angiotensin II Receptor Blockers may make angiotensin-converting enzyme inhibitors more harmful or toxic. Angiotensin-Converting Enzyme Inhibitors' serum levels may rise in response to angiotensin II receptor blockers. Management: According to US labelling, it is not advisable to take telmisartan and ramipril. It is unclear whether another ACE inhibitor and ARB combo would be any safer. When possible, take into account alternatives to the mix. |
|
Bile Acid Sequestrants |
The absorption of thiazide and thiazide-like diuretics may be reduced. Also reduced is the diuretic reaction. |
|
Colesevelam |
May lower the level of Olmesartan in the serum. Olmesartan should be administered at least 4 hours before colestipol. |
|
Lithium |
The excretion of lithium may be reduced by thiazide and thiazide-like diuretics. |
|
Lithium |
It's possible that angiotensin II receptor blockers will raise the level of lithium in the blood. Management: After adding an angiotensin II receptor antagonist, it will probably be necessary to lower the dosage of lithium. |
|
Obinutuzumab |
The hypotensive effects of blood pressure-lowering medications may be strengthened. Management: Take into account temporarily stopping blood pressure-lowering drugs 12 hours before the start of the obinutuzumab infusion and keeping them off until 1 hour after the infusion is finished. |
|
Sodium Phosphates |
Angiotensin II Receptor Blockers may make sodium phosphates more nephrotoxic. In particular, there may be an increased risk of acute phosphate nephropathy. Treatment: You might want to temporarily stop taking ARBs or look into alternatives to the oral sodium phosphate bowel preparation in order to prevent this combo. Maintaining appropriate hydration and properly monitoring renal function should be done if the combination cannot be avoided. |
|
Sodium Phosphates |
The nephrotoxic effects of sodium phosphates may be increased by diuretics. In particular, there may be an increased risk of acute phosphate nephropathy. Treatment: You might want to temporarily stop taking diuretics or look for an alternative to the oral sodium phosphate bowel preparation in order to prevent this combo. If the combination cannot be avoided, drink well and keep an eye on your kidney and fluid levels. |
|
Tolvaptan |
May raise the level of OATP1B1/1B3 (SLCO1B1/1B3) Substrates in the serum. |
|
Topiramate |
The hypokalemic impact of topiramate may be enhanced by thiazide and thiazide-like diuretics. The blood concentration of topiramate may rise in response to thiazide and thiazide-like diuretics. When using a thiazide diuretic, monitor for elevated topiramate levels and any negative consequences (such as hypokalemia). Serum potassium levels should be closely watched when receiving concurrent treatment. There may be a need to lower topiramate dosage. |
|
Risk Factor X (Avoid combination) |
|
|
Aminolevulinic Acid (Systemic) |
Aminolevulinic Acid's photosensitizing impact may be enhanced by photosensitizing agents (Systemic). |
|
Bromperidol |
The hypotensive impact of bromperidol may be enhanced by blood pressure lowering medications. Blood Pressure Lowering Agents' hypotensive effects may be lessened by bromperidol. |
|
Dofetilide |
The QTc-prolonging action of dofetilide may be strengthened by hydrochlorothiazide. The serum levels of Dofetilide may rise in response to HydroCHLOROthiazide. |
|
Levosulpiride |
Thiazide and Thiazide-Like Diuretics may intensify Levosulpiride's negative/toxic effects. |
|
Mecamylamine |
Sulfonamides may intensify Mecamylamine's harmful or hazardous effects. |
|
Promazine |
Promazine's ability to prolong QTc may be enhanced by thiazide and thiazide-like diuretics. |
Monitoring Parameters:
- Blood pressure, serum electrolytes, BUN, creatinine
How to administer Olmesartan and hydrochlorothiazide (Benicar HCT)?
P/O:
- Administer with or without food.
Mechanism of action of Olmesartan and hydrochlorothiazide (Benicar HCT):
- Angiotensin II's vasoconstrictor and aldosterone-secreting actions are blocked by olmesartan.
- The drug hydrochlorothiazide increases the excretion of sodium, water, and potassium ions by reducing sodium reabsorption from the distal tubules.
See individual agents (Olmesartan and Hydrochlorothiazide)
International Brands of Olmesartan and hydrochlorothiazide (Benicar HCT):
- Benicar HCT
- Olmetec Plus
- Abetis Plus
- Almetec CO
- Alteisduo
- Alzor HCT
- Cardosal Plus
- CoOLMETEC
- Fu Ao Tan
- Iltux HCT
- Olme-H
- Olmegan
- Olmesan Plus
- Olmetec Comp
- Olmetec D
- Olmetec HCT
- Olmetec HCTZ
- Olmetec Plus
- Olmetec Plus H
- Olmezar Plus
- Omesar Plus
- Openvas CO
- Orbas Plus
Olmesartan and hydrochlorothiazide Brand Names in Pakistan:
Olmesartan and hydrochlorothiazide Tablets 20 mg |
|
| Co-Baritec | Barrett Hodgson Pakistan (Pvt) Ltd. |
| Co-Olesta | Searle Pakistan (Pvt.) Ltd. |
| Malisartan -Ht | Alied Medical |
| Olmipress -H | Remington Pharmaceutical Industries (Pvt) Ltd. |
| Omsana Diu | Hilton Pharma (Pvt) Limited |
| Orion Diu | Ferozsons Laboratoies Ltd. |
| Oscord Diu | Hilton Pharma (Pvt) Limited |
| Sofvasc-Olm | Wilsons Pharmaceuticals |
Olmesartan and hydrochlorothiazide Tablets 40 mg |
|
| Benicar-H | Himont Pharmaceuticals (Pvt) Ltd. |
| Co-Baritec | Barrett Hodgson Pakistan (Pvt) Ltd. |
| Co-Olesta | Searle Pakistan (Pvt.) Ltd. |
| Malisartan -Ht | Alied Medical |
| Olmipress -H | Remington Pharmaceutical Industries (Pvt) Ltd. |
| Omsana Diu | Hilton Pharma (Pvt) Limited |
| Oscord Diu | Hilton Pharma (Pvt) Limited |
| Sofvasc-Olm | Wilsons Pharmaceuticals |
 Injection.webp)